Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
treatment publishing date : 2021 - 12 - 13 save search
New Data from MajesTEC-1 Study Show Continued Deep and Durable Responses of Teclistamab (BCMAxCD3 Bispecific Antibody) in Treatment of Heavily Pretreated Patients with Multiple Myeloma
Published: 2021-12-13 (Crawled : 01:00) - prnewswire.com
GNMSF | $290.38 220
|
Health Technology
|
| O: -3.62%
H: 5.16%
C: 4.16%
JNJ | News | $147.17 0.98% 3.2M
|
Health Technology
|
| O: 1.9%
H: 0.0%
C: 0.0%
GMAB | $28.68 1.23% 150K
|
Health Technology
|
| O: -4.01%
H: 1.01%
C: -2.07%
AMGN | $267.41 1.77% 1.4M
|
Health Technology
|
| O: 0.22%
H: 1.65%
C: 1.15%
treatment antibody
Teleflex Receives Reimbursement Approval for the UroLift® System in JapanWill expand patient access to breakthrough BPH treatment
Published: 2021-12-13 (Crawled : 23:00) - biospace.com/
TFX | News | $206.23 -0.56% 140K
|
Health Technology
|
| O: -0.09%
H: 0.0%
C: 0.0%
urolift treatment approval
COMPASS Pathways announces positive outcome of 25mg COMP360 psilocybin therapy as adjunct to SSRI antidepressants in open-label treatment-resistant depression study
Published: 2021-12-13 (Crawled : 22:00) - biospace.com/
CMPS | $8.365 -0.65% 200K
|
Health Technology
|
| O: -5.04%
H: 0.0%
C: 0.0%
comp360 treatment positive therapy depression psilocybin
Yescarta® ZUMA-12 Study Demonstrates 78% Complete Response Rate as Part of First-Line Treatment in Newly Diagnosed High-Risk Large B-Cell Lymphoma
Published: 2021-12-13 (Crawled : 22:00) - biospace.com/
GILD | News | $66.45 0.44% 4.3M
|
Health Technology
|
| O: -0.09%
H: 0.0%
C: 0.0%
zuma-12 yescarta treatment risk t-cell
Junshi Biosciences and Coherus Announce Positive Interim Overall Survival Results of CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer
Published: 2021-12-13 (Crawled : 21:00) - globenewswire.com
ABBV | News | $166.43 1.08% 2M
|
Health Technology
|
| O: 1.07%
H: 0.0%
C: 0.0%
CHRS | $1.995 -0.25% 2M
|
Health Technology
|
| O: -0.83%
H: 0.0%
C: 0.0%
hoice-01 treatment trial lung cancer positive therapy bioscience results cancer phase 3
Veru Announces FDA Approval of ENTADFI, a New Treatment for Benign Prostatic Hyperplasia
Published: 2021-12-13 (Crawled : 15:30) - biospace.com/
VERU | $1.365 -3.87% 1.7M
|
Health Technology
|
| O: 9.28%
H: 0.0%
C: 0.0%
treatment fda fda approval approval
Rocket Pharmaceuticals Presents Positive Clinical Data from Company’s Lentiviral Gene Therapies for Treatment of Fanconi Anemia, LAD-I and PKD at the 63rd American Society of Hematology (ASH) Annual Meeting
Published: 2021-12-13 (Crawled : 15:00) - biospace.com/
RCKT M | $22.455 -4.37% 540K
|
Health Technology
|
| O: 1.14%
H: 0.0%
C: 0.0%
treatment ema als anemia gene therapies positive gene therapy
X4 Pharmaceuticals Presents New Clinical and Scientific Data at 2021 ASH Annual Meeting Supporting Broader Potential for Mavorixafor in the Treatment of Primary Immunodeficiencies
Published: 2021-12-13 (Crawled : 14:30) - biospace.com/
XFOR | $1.275 6.25% 2.3M
|
Health Technology
|
| O: -25.95%
H: 0.0%
C: 0.0%
treatment als potential
Intellia Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of NTLA-2002 for the Treatment of Hereditary Angioedema
Published: 2021-12-13 (Crawled : 14:30) - biospace.com/
NTLA | $20.99 -1.55% 560K
|
Health Technology
|
| O: 1.12%
H: 0.0%
C: 0.0%
ntla-2002 treatment ema trial therapeutics intel phase 1 hereditary angioedema
electroCore Announces New Patent for Stroke and TIA Treatment
Published: 2021-12-13 (Crawled : 14:00) - globenewswire.com
ECOR | $5.77 2.31% 6.8K
|
Health Technology
|
| O: 2.03%
H: 0.0%
C: 0.0%
treatment patent stroke
Nuvation Bio Announces FDA Clearance of Investigational New Drug Application for NUV-422 for the Treatment of Prostate Cancer
Published: 2021-12-13 (Crawled : 13:00) - biospace.com/
NUVB A | $2.645 2.52% 580K
|
|
| O: -0.11%
H: 0.0%
C: 0.0%
nuv-422 new drug treatment fda clearance prostate cancer application drug fda clearance cancer
MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of ALS
Published: 2021-12-13 (Crawled : 12:30) - biospace.com/
MNOV | $1.4 9.6K
|
Health Technology
|
| O: 2.22%
H: 0.0%
C: 0.0%
mn-166 treatment patent als parkinson
BELLUS Health Announces Positive Topline Results from its Phase 2b SOOTHE Trial of BLU-5937 for the Treatment of Refractory Chronic Cough
Published: 2021-12-13 (Crawled : 12:30) - biospace.com/
BLU | $14.74 0.03% 0
|
Health Technology
|
| O: 35.91%
H: 0.0%
C: 0.0%
blu-5937 treatment health phase 2 phase 2b trial topline results positive results topline chronic cough
4D pharma announces positive topline results from Part A of Phase I/II trial of MRx-4DP0004 for the treatment of asthma
Published: 2021-12-13 (Crawled : 08:00) - 4dpharmaplc.com
LBPS | $1.65 -0.61%
|
Manufacturing
|
| O: -4.06%
H: 0.0%
C: 0.0%
dp0004 treatment trial topline results positive results topline
PharmaMar and Jazz Pharmaceuticals Announce Initiation of Confirmatory Phase 3 Clinical Trial of Zepzelca® (lurbinectedin) for the Treatment of Patients with Relapsed Small Cell Lung Cancer
Published: 2021-12-13 (Crawled : 08:00) - prnewswire.com
JAZZ | $110.6 1.22% 210K
|
Health Technology
|
| O: -1.06%
H: 0.0%
C: 0.0%
zepzelca treatment trial lung cancer cancer phase 3
Gainers vs Losers
| 71% | 29% |
Top 10 Gainers
AGBA | News | $1.27 217.5% 120M
|
Finance
EGOX | $0.0503 39.72% 320M
|
RWOD | $10.52 31.56% 5.9M
|
n/a
ZCMD | $1.905 31.38% 30M
|
Commercial Services
NVFY | $2.71 28.44% 31M
|
Consumer Durables
MRDB 4 | $0.536 27.65% 2M
|
n/a
BSFC | $0.0822 27.64% 75M
|
Manufacturing
TPET | $0.4121 25.68% 45M
|
n/a
INDO | $5.1 25.0% 15M
|
Energy Minerals
CHRO | $1.53 24.9% 100K
|
n/a
Your saved searches
Save your searches and get alerts when important news are released.